© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure
aInstitut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg–Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
bInstitut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen, Germany
*Corresponding author. Tel.: +49-40-428032180; fax: +49-40-428034876. Email address: t.eschenhagen{at}uke.uni-hamburg.de
Heart failure is accompanied by stereotypic alterations in cardiac gene expression. These changes are most likely secondary in the pathogenesis and can be viewed as protective, e.g. as energy-saving mechanisms, but at the same time, they aggravate contractile dysfunction and the deficit of failing cardiac myocytes to respond to altered hemodynamic needs. One of the best-studied, paradigmatic examples of this dichotomy is heterologous desensitization of the cardiac adenylyl cyclase (AC) signaling pathway. It protects against detrimental consequences of the excessive adrenergic drive, but it also blunts the most powerful inotropic support of the heart. Desensitization is associated with downregulation of β-adrenergic receptors, increased β-adrenoceptor kinases and increased inhibitory G protein
-subunits, G
i. Whereas a causative role of the former is generally accepted, the role of the increase in G
i has remained controversial for many years. The present article summarizes early and novel findings that, in the view of the authors, provide solid evidence for G
i to play an important role in the adaptation of cardiac AC to various pathophysiological conditions.
KEYWORDS G-proteins; Beta-adrenergic desensitization; Heart failure; Adenovirus; Betablocker
Time for primary review 21 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. Schmechel, M. Grimm, A. El-Armouche, G. Hoppner, A. P. Schwoerer, H. Ehmke, and T. Eschenhagen Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects Cardiovasc Res, April 1, 2009; 82(1): 100 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chakir, S. K. Daya, T. Aiba, R. S. Tunin, V. L. Dimaano, T. P. Abraham, K. Jaques, E. W. Lai, K. Pacak, W.-Z. Zhu, et al. Mechanisms of Enhanced {beta}-Adrenergic Reserve From Cardiac Resynchronization Therapy Circulation, March 10, 2009; 119(9): 1231 - 1240. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hilal-Dandan, H. He, J. L. Martin, L. L. Brunton, and W. H. Dillmann Endothelin downregulates SERCA2 gene and protein expression in adult rat ventricular myocytes: regulation by pertussis toxin-sensitive Gi protein and cAMP Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H728 - H734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Blumer, K. Lord, T. L. Saunders, A. Pacchioni, C. Black, E. Lazartigues, K. J. Varner, T. W. Gettys, and S. M. Lanier Activator of G Protein Signaling 3 Null Mice: I. Unexpected Alterations in Metabolic and Cardiovascular Function Endocrinology, August 1, 2008; 149(8): 3842 - 3849. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bisping, G. Tenderich, P. Barckhausen, B. Stumme, S. Bruns, D. von Lewinski, and B. Pieske Atrial myocardium is the predominant inotropic target of adrenomedullin in the human heart Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3001 - H3007. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Fernandez-Twinn, S. Ekizoglou, A. Wayman, C. J. Petry, and S. E. Ozanne Maternal low-protein diet programs cardiac beta-adrenergic response and signaling in 3-mo-old male offspring Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2006; 291(2): R429 - R436. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bennett, R. P. Mahajan, J. E. March, P. A. Kemp, and S. M. Gardiner Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats Br. J. Anaesth., September 1, 2004; 93(3): 400 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. El-Armouche, T. Pamminger, D. Ditz, O. Zolk, and T. Eschenhagen Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts Cardiovasc Res, January 1, 2004; 61(1): 87 - 93. [Abstract] [Full Text] [PDF] |
||||






